Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage 3 Melanoma
University of Texas MD Anderson Cancer CenterThe phase II study was led by researchers at The University of Texas MD Anderson Cancer Center. Results of the study, the first randomized neoadjuvant clinical trial of immune checkpoint blockade for melanoma patients, are reported in Nature Medicine.